Dihydroquinoline pyrazolyl compounds

1. A compound of formula (I)

wherein:

R 1 , R 5 , R 6 , R 7 and R 8 in each occurrence are independently selected from H, alkyl, haloalkyl, cycloalkyl and halocycloalkyl;

R 2 , R 3 and R 4 in each occurrence are independently selected from H, halogen, alkyl, haloalkyl, cycloalkyl and halocycloalkyl;

R 9 , R 12 , R 13 , R 16 and R 17 in each occurrence are (i) independently selected from H, alkyl and cycloalkyl, and, R 11 together with R 14 form —CH 2 CH 2 —, or, (ii) R 9 , R 16 and R 17 in each occurrence are independently selected from H, alkyl and cycloalkyl and R 12 together with R 11 and R 13 together with R 14 both form —CH 2 ;

R 10 is alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroaryl alkyl, wherein substituted aryl, substituted arylalkyl, substituted heteroaryl and substituted heteroarylalkyl are substituted with one to three substituents selected from alkyl, halogen, haloalkyl, cycloalkyl, halocycloalkyl, cyano, alkoxy, haloalkoxy, alkylsulfanyl, haloalkylsulfanyl, alkyl sulfonyl and haloalkylsulfonyl;

A is —C(O)— or —S(O) 2 —

n is zero or 1;

m is 1;

or, pharmaceutically acceptable salts thereof.

2. The compound according to claim 1 , wherein R 1 is alkyl.

3. The compound according to claim 1 wherein R 5 , R 6 , R 7 and R 8 are H.

4. The compound according to claim 1 wherein R 2 is H.

5. The compound according to claim 1 wherein one of R 3 and R 4 is H and the other one is halogen.

6. The compound according to claim 1 wherein R 3 and R 4 are H.

7. The compound according to claim 1 wherein R 16 is H or alkyl.

8. The compound according to claim 1 wherein R 9 , R 12 , R 13 and R 17 are H.

9. The compound according to claim 1 wherein R 9 , R 12 , R 13 , R 16 and R 17 are H.

10. The compound according to claim 1 wherein n is 1.

11. The compound according to claim 1 wherein A is —C(O)—.

12. The compound according to claim 1 wherein R 9 , R 12 , R 13 , R 16 and R 17 in each occurrence are independently selected from H, alkyl and cycloalkyl, and, R 11 together with R 14 form —CH 2 CH 2 —.

13. The compound according to claim 1 wherein R 9 , R 16 and R 17 in each occurrence are independently selected from H, alkyl and cycloalkyl and R 12 together with R 11 and R 13 together with R 14 both form —CH 2 .

14. The compound according to claim 1 wherein R 10 is alkyl or heteroaryl substituted with one to three substituents selected from alkyl, halogen, cyano, alkoxy, alkylsulfanyl and alkyl sulfonyl.

15. The compound according to claim 14 wherein R 10 is alkyl or substituted pyrazolyl, substituted imidazolyl or substituted pyridinyl.

16. The compound according to claim 15 , wherein R 10 is alkyl or substituted pyrazolyl, substituted imidazolyl or substituted pyridinyl, wherein substituted pyrazolyl, substituted imidazolyl and substituted pyridinyl are substituted with one alkyl or one halogen.

17. The compound according to claim 16 wherein R 10 is substituted pyrazolyl, substituted imidazolyl or substituted pyridinyl.

18. The compound according to claim 1 which compound is selected from the group consisting of:

6-[4-[(1-Acetyl-4-piperidyl)methyl]-1H-pyrazol-3-yl]-1-methyl-3,4-dihydroquinolin-2-one;

1-Methyl-6-[4-[[1-(1-methylpyrazole-4-carbonyl)-4-piperidyl]methyl]-1H-pyrazol-3-yl]-3,4-dihydroquinolin-2-one;

6-[4-[(1-Ethylsulfonyl-4-piperidyl)methyl]-1H-pyrazol-3-yl]-1-methyl-3,4-dihydroquinolin-2-one;

6-[4-[(1-Acetylpiperidin-4-yl)methyl]-1H-pyrazol-3-yl]-7-fluoro-1-methyl-3,4-dihydroquinolin-2-one;

5-Fluoro-1-methyl-6-[4-[[1-(1-methylpyrazole-4-carbonyl)piperidin-4-yl]methyl]-1H-pyrazol-3-yl]-3,4-dihydroquinolin-2-one;

6-[4-[(1-Acetylpiperidin-4-yl)methyl]-1H-pyrazol-3-yl]-5-fluoro-1-methyl-3,4-dihydroquinolin-2-one;

6-[4-[(1-Ethylsulfonylpiperidin-4-yl)methyl]-1H-pyrazol-3-yl]-5-fluoro-1-methyl-3,4-dihydroquinolin-2-one;

5-Fluoro-1-methyl-6-[4-[[1-(2-methylpyrazole-3-carbonyl)piperidin-4-yl]methyl]-1H-pyrazol-3-yl]-3,4-dihydroquinolin-2-one;

5-Fluoro-1-methyl-6-[4-[[1-(1-methylimidazole-2-carbonyl)piperidin-4-yl]methyl]-1H-pyrazol-3-yl]-3,4-dihydroquinolin-2-one;

6-[4-[(1-Acetylpiperidin-4-yl)methyl]-1H-pyrazol-3-yl]-5-chloro-1-methyl-3,4-dihydroquinolin-2-one;

1-Methyl-6-[4-[[1-(2-methylpyrazole-3-carbonyl)-4-piperidyl]methyl]-1H-pyrazol-3-yl]-3,4-dihydroquinolin-2-one;

5-Chloro-1-methyl-6-[4-[[1-(1-methylpyrazole-4-carbonyl)-4-piperidyl]methyl]-1H-pyrazol-3-yl]-3,4-dihydroquinolin-2-one;

5-Chloro-6-[4-[[1-(3-chloropyridine-2-carbonyl)-4-piperidyl]methyl]-1H-pyrazol-3-yl]-1-methyl-3,4-dihydroquinolin-2-one;

5-Chloro-1-methyl-6-[4-[[1-(2-methylpyrazole-3-carbonyl)-4-piperidyl]methyl]-1H-pyrazol-3-yl]-3,4-dihydroquinolin-2-one;

5-Chloro-6-[4-[[1-(3-chloropyridine-4-carbonyl)-4-piperidyl]methyl]-1H-pyrazol-3-yl]-1-methyl-3,4-dihydroquinolin-2-one;

1-Methyl-6-[4-[[1-(3-methylimidazole-4-carbonyl)-4-piperidyl]methyl]-1H-pyrazol-3-yl]-3,4-dihydroquinolin-2-one;

1-Methyl-6-[4-[[1-(1-methylimidazole-2-carbonyl)-4-piperidyl]methyl]-1H-pyrazol-3-yl]-3,4-dihydroquinolin-2-one;

1-Methyl-6-[4-[[1-(4-methylpyridine-3-carbonyl)-4-piperidyl]methyl]-1H-pyrazol-3-yl]-3,4-dihydroquinolin-2-one;

6-[4-[[1-(3-Chloropyridine-2-carbonyl)-4-piperidyl]methyl]-1H-pyrazol-3-yl]-1-methyl-3,4-dihydroquinolin-2-one;

(rac)-6-[4-[1-(1-Acetylpiperidin-4-yl)ethyl]-1H-pyrazol-3-yl]-7-fluoro-1-methyl-3,4-dihydroquinolin-2-one;

(rac)-6-[4-[1-(1-Acetylpiperidin-4-yl)ethyl]-1H-pyrazol-3-yl]-5-fluoro-1-methyl-3,4-dihydroquinolin-2-one;

6-[4-[(1S or 1R)-1-(1-Acetylpiperidin-4-yl)ethyl]-1H-pyrazol-3-yl]-5-fluoro-1-methyl-3,4-dihydroquinolin-2-one;

6-[4-[(1R or 1S)-1-(1-Acetylpiperidin-4-yl)ethyl]-1H-pyrazol-3-yl]-5-fluoro-1-methyl-3,4-dihydroquinolin-2-one;

5-Chloro-6-[4-[(2-ethylsulfonyl-2-azaspiro[3.3]heptan-6-yl)methyl]-1H-pyrazol-3-yl]-1-methyl-3,4-dihydroquinolin-2-one;

6-[4-[(2-Acetyl-2-azaspiro[3.3]heptan-6-yl)methyl]-1H-pyrazol-3-yl]-5-chloro-1-methyl-3,4-dihydroquinolin-2-one; and,

5-Chloro-1-methyl-6-[4-[[2-(1-methylpyrazole-4-carbonyl)-2-azaspiro[3.3]heptan-6-yl]methyl]-1H-pyrazol-3-yl]-3,4-dihydroquinolin-2-one; or,

a pharmaceutically acceptable salts thereof.

19. A process to prepare a compound according to claim 1 comprising the reaction of a compound of formula (II) in the presence of a compound of formula (III);

wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , m and n are are as defined in claim 1 and X is halogen or hydroxy.

20. A pharmaceutical composition comprising a compound according to claim 1 and at least one pharmaceutically acceptable carrier, diluent or excipient.